ストックスクリーナーアプリを入手
1.47
0.68%
-0.01
前日終値:
$1.48
開ける：
$1.48
24時間の取引高:
5,807
Relative Volume:
0.22
時価総額：
$72.10M
収益：
-
当期純損益:
$-9.51M
株価収益率:
-7.7368
EPS:
-0.19
ネットキャッシュフロー:
$-10.96M
1週間 パフォーマンス:
-6.37%
1か月 パフォーマンス:
-21.39%
6か月 パフォーマンス:
-19.23%
1年 パフォーマンス:
+8.89%
1日の値動き範囲:
$1.47
$1.52
1週間の範囲:
$1.45
$1.61
52週間の値動き範囲:
$1.12
$2.55
Medicinova Inc Stock (MNOV) Company Profile
MNOV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MNOV
Medicinova Inc
|
1.47 | 72.10M | 0 | -9.51M | -10.96M | -0.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Medicinova Inc Stock (MNOV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-03-10 | 開始されました | Maxim Group | Buy |
| 2019-03-25 | 再開されました | B. Riley FBR | Buy |
| 2018-03-28 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-04-18 | 開始されました | Credit Suisse | Outperform |
| 2013-01-04 | 繰り返されました | Ladenburg Thalmann | Buy |
| 2012-05-24 | ダウングレード | MLV & Co | Buy → Hold |
| 2011-10-18 | 繰り返されました | MLV Capital | Buy |
| 2011-06-22 | 開始されました | Global Hunter Securities | Buy |
| 2010-05-12 | 開始されました | Wedbush | Outperform |
| 2008-11-12 | 繰り返されました | Ladenburg Thalmann | Buy |
| 2008-05-15 | 開始されました | Rodman & Renshaw | Mkt Outperform |
| 2007-07-09 | 開始されました | Punk, Ziegel & Co | Buy |
すべてを表示
Medicinova Inc (MNOV) 最新ニュース
Idiopathic Pulmonary Fibrosis Management Market Top Companies - openPR
MediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at StockNews.com - Defense World
Y Intercept Hong Kong Ltd Makes New $78,000 Investment in MediciNova, Inc. (NASDAQ:MNOV) - Defense World
StockNews.com Initiates Coverage on MediciNova (NASDAQ:MNOV) - Defense World
Pulmonary Fibrosis Therapeutics Market Size in the 7MM - openPR
Idiopathic Pulmonary Fibrosis Management Market Key Players - openPR
MediciNova (NASDAQ:MNOV) Releases Earnings Results, Hits Estimates - MarketBeat
D. Boral Capital Reiterates Buy Rating for MediciNova (NASDAQ:MNOV) - Defense World
MediciNova (NASDAQ:MNOV) Releases Quarterly Earnings Results, Meets Estimates - MarketBeat
StockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV) - Defense World
MediciNova (MNOV) to Release Quarterly Earnings on Thursday - MarketBeat
MediciNova (NASDAQ:MNOV) Now Covered by StockNews.com - MarketBeat
MediciNova (MNOV) Projected to Post Quarterly Earnings on Thursday - Defense World
MediciNova (NASDAQ:MNOV) Now Covered by Analysts at StockNews.com - Defense World
US Exchange Penny Stocks To Watch In January 2025 - Yahoo Finance
MediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.com - Defense World
Jane Street Group LLC Takes $30,000 Position in MediciNova, Inc. (NASDAQ:MNOV) - Defense World
MediciNova (NASDAQ:MNOV) Share Price Crosses Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
MediciNova (NASDAQ:MNOV) Stock Crosses Above 200-Day Moving AverageWhat's Next? - MarketBeat
MediciNova, Inc. (NASDAQ:MNOV) Shares Acquired by Geode Capital Management LLC - Defense World
MediciNova (NASDAQ:MNOV) Coverage Initiated at StockNews.com - Defense World
MediciNova (NASDAQ:MNOV) Shares Pass Above 200-Day Moving Average – Time to Sell? - Defense World
MediciNova (NASDAQ:MNOV) Stock Passes Above 200-Day Moving AverageHere's What Happened - MarketBeat
US Penny Stocks To Watch In December 2024 - Simply Wall St
MediciNova (NASDAQ:MNOV) Stock Passes Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
MNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial… - MSN
MNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial - Smartkarma
Drug Trial Shows Positive Interim Results for ALS Treatment - Streetwise Reports
MediciNova Presents Study Update and Interim Analysis of - GlobeNewswire
MediciNova Reports Strong Interim Data from ALS Drug Trial, Shows Promising Correlations - StockTitan
MediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at D. Boral Capital - Defense World
MediciNova stock undervalued? D. Boral sees upside in ALS & MS market opportunities - Investing.com India
This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Medicinova Inc (MNOV) 財務データ
収益
当期純利益
現金流量
EPS
1.39%
0.55%
大文字化:
|
ボリューム (24 時間):